Adenoid Cystic Carcinoma of Salivary Glands: A Ten-Year Review and an Assessment of the Current Management, Surgery, Radiotherapy, and Chemotherapy

Table 3

Update of the novel and potential therapies used in treating ACC in areas different from salivary glands.

Study/author	Investigated target	Potential use	Comments
(Doddapaneni et al.) [116]	Fibroblast growth factor receptor 1 (FGFR1)	Therapeutic target	Used for ACC of lacrimal glands
(Udagawa et al.) [117]	Liposomal formulation of eribulin (E7389-LF)	Therapeutic agent	Used for ACC of salivary glands, thymus gland, and other sites
(Andersson et al.) [118]	Targeting the oncogenic transcriptional regulator MYB by inhibition of IGF1R/AKT signaling	Therapeutic target	Used for ACC of salivary glands, ACC lacrimal glands, and other sites
(Tchekmedyian et al.) [109]	The multitargeted tyrosine kinase inhibitor lenvatinib	Therapeutic agent	Used for ACC of salivary glands, lacrimal glands, breast, bronchi, and the external auditory canal